Emergent Biosolutions Inc. (NYSE:EBS) Given Consensus Recommendation of “Hold” by Analysts

Emergent Biosolutions Inc. (NYSE:EBS) has been given a consensus recommendation of “Hold” by the six ratings firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $10.00.

Several research analysts have weighed in on the company. UBS Group reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a report on Friday, August 21st. They issued an “underweight” rating on the stock. Benchmark restated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Finally, Weiss Ratings upgraded shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, August 21st.

Insider Activity

In other news, SVP Paul Williams sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the completion of the sale, the senior vice president owned 159,098 shares in the company, valued at $1,336,423.20. This trade represents a 1.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Emergent Biosolutions

Institutional investors and hedge funds have recently bought and sold shares of the company. Integrated Wealth Concepts LLC bought a new stake in shares of Emergent Biosolutions in the second quarter valued at $29,000. Legal & General Group Plc purchased a new stake in Emergent Biosolutions during the 2nd quarter worth about $31,000. Public Employees Retirement System of Ohio purchased a new position in Emergent Biosolutions during the 2nd quarter valued at about $36,000. CANADA LIFE ASSURANCE Co bought a new stake in shares of Emergent Biosolutions during the fourth quarter valued at about $45,000. Finally, California State Teachers Retirement System boosted its position in shares of Emergent Biosolutions by 112.8% in the second quarter. California State Teachers Retirement System now owns 6,008 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 3,185 shares during the period. 78.40% of the stock is owned by institutional investors.

Emergent Biosolutions Stock Down 5.6%

Emergent Biosolutions stock opened at $5.67 on Thursday. Emergent Biosolutions has a fifty-two week low of $4.36 and a fifty-two week high of $14.06. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42. The firm’s 50-day simple moving average is $6.54 and its 200 day simple moving average is $7.80. The stock has a market cap of $290.44 million, a PE ratio of -1.60 and a beta of 2.34.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. The firm had revenue of $234.30 million during the quarter, compared to analyst estimates of $177.50 million. Research analysts predict that Emergent Biosolutions will post 0.13 EPS for the current fiscal year.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.